The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer

Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) monoclonal antibodies, have demonstrated survival benefits compared with standard therapies in various advanced cancers. Notably, non-small cell lung cancer (NSCLC) has become a main target of immunotherapy using ICIs. In previously treated NSCLC patients, nivolumab, pembrolizumab and atezolizumab have demonstrated superiority to docetaxel in terms of overall survival (OS)[1 –3].

Source: Lung Cancer - December 26, 2018 Category: Cancer & Oncology Authors: Kentaro Ito, Satoru Miura, Tadashi Sakaguchi, Kenta Murotani, Nobuyuki Horita, Hiroaki Akamatsu, Kohei Uemura, Satoshi Morita, Nobuyuki Yamamoto Source Type: research